SFM StemPro™-34 (1X)
SFM StemPro™-34 (1X)
Gibco™

SFM StemPro™-34 (1X)

El SFM StemPro-34 es un medio de cultivo sin suero formulado específicamente para apoyar el desarrollo de células hematopoyéticas humanasMás información
Have Questions?
Número de catálogoCantidad
10639011500 mL
Número de catálogo 10639011
Precio (USD)
721,50
Each
Añadir al carro de la compra
Cantidad:
500 mL
Precio (USD)
721,50
Each
Añadir al carro de la compra
El SFM StemPro-34 es un medio de cultivo sin suero formulado específicamente para apoyar el desarrollo de células hematopoyéticas humanas en cultivo, incluidas las HSC y las células progenitoras aisladas a partir de la médula ósea, sangre del cordón umbilical y sangre periférica. El SFM StemPro-34 es un medio de cultivo celular flexible que se puede utilizar para una amplia variedad de aplicaciones.
Diseñado para aplicaciones de procesamiento de cultivos celulares y de tejido ex vivo. PRECAUCIÓN: Cuando se utiliza como dispositivo médico, la ley federal restringe su venta a los médicos o por orden de estos.
Especificaciones
Tipo de célulaCélula madre hematopoyética, célula hematopoyética, médula ósea
Nivel de endotoxinas≤10 EU/mL
Línea de productosStemPro
Tipo de productoMedio libre de suero (SFM) de células madre
Cantidad500 mL
EspecieHumano
ClasificaciónSin suero
Culture TypeSuspensión estacionaria
FormularioLíquido
Serum LevelSin suero
Con aditivosRojo de fenol
Sin aditivosSin glutamina
Unit SizeEach
Contenido y almacenamiento
• 500 ml de medio sin suero StemPro™-34- (almacenar de 2 °C a 8 °C en la oscuridad)
• 13 ml de suplemento de nutriente StemPro™-34 (almacenar de – 5 °C a – 20 °C en la oscuridad)

Almacenar el medio completo de 2 °C a 8 °C en la oscuridad.

Citations & References (17)

Citations & References
Abstract
Functional profiling of single CRISPR/Cas9-edited human long-term hematopoietic stem cells.
Authors:Wagenblast E,Azkanaz M,Smith SA,Shakib L,McLeod JL,Krivdova G,Araújo J,Shultz LD,Gan OI,Dick JE,Lechman ER
Journal:Nature communications
PubMed ID:31628330
In the human hematopoietic system, rare self-renewing multipotent long-term hematopoietic stem cells (LT-HSCs) are responsible for the lifelong production of mature blood cells and are the rational target for clinical regenerative therapies. However, the heterogeneity in the hematopoietic stem cell compartment and variable outcomes of CRISPR/Cas9 editing make functional interrogation ... More
Ex vivo expanded human cord blood-derived hematopoietic progenitor cells induce lung growth and alveolarization in injured newborn lungs.
Authors:Mao Q,Chu S,Ghanta S,Padbury JF,De Paepe ME
Journal:Respiratory research
PubMed ID:23522153
BACKGROUND: We investigated the capacity of expanded cord blood-derived CD34+ hematopoietic progenitor cells to undergo respiratory epithelial differentiation ex vivo, and to engraft and attenuate alveolar disruption in injured newborn murine lungs in vivo. METHODS: Respiratory epithelial differentiation was studied in CD34+ cells expanded in the presence of growth factors ... More
Human pluripotent stem cells differentiated in fully defined medium generate hematopoietic CD34- and CD34+ progenitors with distinct characteristics.
Authors:Chicha L,Feki A,Boni A,Irion O,Hovatta O,Jaconi M
Journal:PloS one
PubMed ID:21364915
BACKGROUND: Differentiation of pluripotent stem cells in vitro provides a powerful means to investigate early developmental fates, including hematopoiesis. In particular, the use of a fully defined medium (FDM) would avoid biases induced by unidentified factors contained in serum, and would also allow key molecular mediators involved in such a ... More
Development of the hemangioblast defines the onset of hematopoiesis in human ES cell differentiation cultures.
Authors:Kennedy M,D'Souza SL,Lynch-Kattman M,Schwantz S,Keller G
Journal:Blood
PubMed ID:17148580
The onset of hematopoiesis in the mouse embryo and in the embryonic stem (ES) cell differentiation model is defined by the emergence of the hemangioblast, a progenitor with both hematopoietic and vascular potential. While there is evidence for the existence of a hemangioblast in the mouse, it is unclear if ... More
Differentiation of Human-Induced Pluripotent Stem Cells to Macrophages for Disease Modeling and Functional Genomics.
Authors:Shi J,Xue C,Liu W,Zhang H
Journal:Current protocols in stem cell biology
PubMed ID:30537374
Macrophages play important roles in many diseases. We describe a protocol and the associated resources for the differentiation of human induced pluripotent stem cell-derived macrophages (IPSDM) and their applications in understanding human macrophage physiology and relevant diseases. The protocol uses an embryoid body–based approach with a combination of serum-free condition ... More